2010 first Risk Sharing deal with NICE

National Institute for Health and Clinical Excellence

January 2010

Final appraisal determination
Certolizumab pegol for the treatment of rheumatoid arthritis

1 Guidance
1.1 Certolizumab pegol is recommended as an option for the treatment of people with rheumatoid arthritis only if:
certolizumab pegol is used as described for other tumour necrosis factor (TNF)-inhibitor treatments in ‘Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis’ (NICE technology appraisal guidance 130) and
the manufacturer provides the first 12 weeks of certolizumab pegol (10 pre-loaded 200-mg syringes) free of charge to all patients starting treatment.

This is an approximate $4,000 reduction from the first year access cost of Cimzia.